Hepatitis B reactivation after ifosfamide therapy for retroperitoneal sarcoma

Purva Chhibar, Ziqiang Zhu, Naga K.S. Cheedella, Rashid Chaudhry, Jen Chin Wang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Unusual clinical course Background: Patients receiving cancer treatment are at risk for hepatitis B virus (HBV) reactivation. Ifosfamide is an alkylating agent and is considered to be one of the important drugs for the treatment of metastatic sarcoma. No association of ifosfamide and HBV reactivation has been reported so far. Case Report: We report a case of a 61-year-old Asian man with metastatic retroperitoneal liposarcoma who was HBcAb positive and was treated with ifosfamide and dacarbazine, developed HBV reactivation secondary to ifosfamide requiring treatment with tenofovir. To the best of our knowledge, this is the first report describing HBV reactivation in a patient with positive HBcAb who was treated with ifosfamide. Conclusions: We recommend close surveillance of possible HBV reactivation while employing ifosfamide chemotherapy.

Original languageEnglish (US)
Pages (from-to)371-374
Number of pages4
JournalAmerican Journal of Case Reports
Volume17
DOIs
StatePublished - Jun 1 2016

Fingerprint

Ifosfamide
Hepatitis B
Sarcoma
Hepatitis B virus
Tenofovir
Therapeutics
Dacarbazine
Alkylating Agents
Drug Therapy
Pharmaceutical Preparations
Neoplasms

Keywords

  • Antineoplastic Agents
  • Hepatitis B Surface Antigens
  • Ifosfamide

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hepatitis B reactivation after ifosfamide therapy for retroperitoneal sarcoma. / Chhibar, Purva; Zhu, Ziqiang; Cheedella, Naga K.S.; Chaudhry, Rashid; Wang, Jen Chin.

In: American Journal of Case Reports, Vol. 17, 01.06.2016, p. 371-374.

Research output: Contribution to journalArticle

Chhibar, Purva ; Zhu, Ziqiang ; Cheedella, Naga K.S. ; Chaudhry, Rashid ; Wang, Jen Chin. / Hepatitis B reactivation after ifosfamide therapy for retroperitoneal sarcoma. In: American Journal of Case Reports. 2016 ; Vol. 17. pp. 371-374.
@article{97aca4e43fe54c91be6ed3c7ecea35bd,
title = "Hepatitis B reactivation after ifosfamide therapy for retroperitoneal sarcoma",
abstract = "Objective: Unusual clinical course Background: Patients receiving cancer treatment are at risk for hepatitis B virus (HBV) reactivation. Ifosfamide is an alkylating agent and is considered to be one of the important drugs for the treatment of metastatic sarcoma. No association of ifosfamide and HBV reactivation has been reported so far. Case Report: We report a case of a 61-year-old Asian man with metastatic retroperitoneal liposarcoma who was HBcAb positive and was treated with ifosfamide and dacarbazine, developed HBV reactivation secondary to ifosfamide requiring treatment with tenofovir. To the best of our knowledge, this is the first report describing HBV reactivation in a patient with positive HBcAb who was treated with ifosfamide. Conclusions: We recommend close surveillance of possible HBV reactivation while employing ifosfamide chemotherapy.",
keywords = "Antineoplastic Agents, Hepatitis B Surface Antigens, Ifosfamide",
author = "Purva Chhibar and Ziqiang Zhu and Cheedella, {Naga K.S.} and Rashid Chaudhry and Wang, {Jen Chin}",
year = "2016",
month = "6",
day = "1",
doi = "10.12659/AJCR.896496",
language = "English (US)",
volume = "17",
pages = "371--374",
journal = "American Journal of Case Reports",
issn = "1941-5923",
publisher = "International Scientific Literature, Inc",

}

TY - JOUR

T1 - Hepatitis B reactivation after ifosfamide therapy for retroperitoneal sarcoma

AU - Chhibar, Purva

AU - Zhu, Ziqiang

AU - Cheedella, Naga K.S.

AU - Chaudhry, Rashid

AU - Wang, Jen Chin

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Objective: Unusual clinical course Background: Patients receiving cancer treatment are at risk for hepatitis B virus (HBV) reactivation. Ifosfamide is an alkylating agent and is considered to be one of the important drugs for the treatment of metastatic sarcoma. No association of ifosfamide and HBV reactivation has been reported so far. Case Report: We report a case of a 61-year-old Asian man with metastatic retroperitoneal liposarcoma who was HBcAb positive and was treated with ifosfamide and dacarbazine, developed HBV reactivation secondary to ifosfamide requiring treatment with tenofovir. To the best of our knowledge, this is the first report describing HBV reactivation in a patient with positive HBcAb who was treated with ifosfamide. Conclusions: We recommend close surveillance of possible HBV reactivation while employing ifosfamide chemotherapy.

AB - Objective: Unusual clinical course Background: Patients receiving cancer treatment are at risk for hepatitis B virus (HBV) reactivation. Ifosfamide is an alkylating agent and is considered to be one of the important drugs for the treatment of metastatic sarcoma. No association of ifosfamide and HBV reactivation has been reported so far. Case Report: We report a case of a 61-year-old Asian man with metastatic retroperitoneal liposarcoma who was HBcAb positive and was treated with ifosfamide and dacarbazine, developed HBV reactivation secondary to ifosfamide requiring treatment with tenofovir. To the best of our knowledge, this is the first report describing HBV reactivation in a patient with positive HBcAb who was treated with ifosfamide. Conclusions: We recommend close surveillance of possible HBV reactivation while employing ifosfamide chemotherapy.

KW - Antineoplastic Agents

KW - Hepatitis B Surface Antigens

KW - Ifosfamide

UR - http://www.scopus.com/inward/record.url?scp=84985007033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985007033&partnerID=8YFLogxK

U2 - 10.12659/AJCR.896496

DO - 10.12659/AJCR.896496

M3 - Article

C2 - 27246626

AN - SCOPUS:84985007033

VL - 17

SP - 371

EP - 374

JO - American Journal of Case Reports

JF - American Journal of Case Reports

SN - 1941-5923

ER -